Ansell, S. M., Flinn, I., Taylor, M. H., Sikic, B. I., Brody, J., Nemunaitis, J., . . . Yellin, M. J. (2020). Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. Blood Advances, 4(9), 1917-1926. https://doi.org/10.1182/bloodadvances.2019001079

Ansell, Stephen M., et al. "Safety and Activity of Varlilumab, a Novel and First-in-class Agonist Anti-CD27 Antibody, for Hematologic Malignancies." Blood Advances 4, no. 9 (2020): 1917-1926. https://doi.org/10.1182/bloodadvances.2019001079.

Ansell, Stephen M., et al. "Safety and Activity of Varlilumab, a Novel and First-in-class Agonist Anti-CD27 Antibody, for Hematologic Malignancies." Blood Advances, vol. 4, no. 9, 2020, pp. 1917-1926, https://doi.org/10.1182/bloodadvances.2019001079.